Evaluation of Urine Leakage of New Absorbing Incontinence Products in a Home Care Environment

Urinary Incontinence Clinical Trial

Official title:

A Randomized Crossover Study to Evaluate Urine Leakage of Pant Type Absorbing Incontinence Products of Two Absorption Levels in a Home Care Environment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05484388
• Other study ID #: SPRING
• Status: Completed
• Phase: N/A
• Start date: October 3, 2022
• Est. completion date: February 3, 2023

Study information

• Verified date: February 2023
• Source: Essity Hygiene and Health AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this interventional but non-invasive, clinical investigation is to demonstrate the performance and safety of two new class I medical device Absorbing Hygiene Products developed by Essity.

The primary objective is to demonstrate for each of the new products that they provide protection to leakages similar to their corresponding standard of care devices already used on the market. The target population for this clinical investigation are community living individuals suffering from moderate to severe incontinence, who may receive care by a care giving relative, by one or more caregivers and are current users of TENA Pants of the respective absorption level.

Description:

The clinical investigation will be conducted to demonstrate the performance and safety of two new class I medical device Absorbing Hygiene Products developed by Essity. The performance of the new design will be compared to that of the currently marketed TENA Pants, deemed state of the art.

To ensure that the personal preference of the study subjects are met, only current users of the marketed TENA pants will be recruited. To meet the objectives, the investigation is designed to be prospective, randomized, cross-over and interventional but not invasive with two different groups each testing one investigational-reference device pair matched to the currently used product at the time of inclusion. The study subjects will act as their own control, using one device for 10 (+ max. 3) days and then switching to the other device for additional 10 (+ max. 3) days. As for most users the avoidance of urinary leakages is the primary concern, this will be the primary outcome of the clinical investigation for each of the device pairs tested.

The used products will be collected, weighed and photographed. A subject/caregiver questionnaire will collect data on subject satisfaction and preferences. A skin health assessment will also be performed to evaluate any change in subject skin health before, during and at the end of the study.

Since the devices perform well in their intended use, leakage rate of each individual device is low, so a large number of devices needs to be tested per absorption level in order to obtain a robust assessment. Since the underlying incontinence condition is not affected by participation in the investigation, a sequential measurement series should be sufficient to meet the study objectives.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: February 3, 2023
• Est. primary completion date: December 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• criteria to be eligible for this clinical investigation:

1. Subject is diagnosed with moderate to severe urinary incontinence managed only with TENA Pants absorbent hygiene products of size Medium or Large with the same absorption level that is used in the study since at least 4 weeks.

2. Subject is living at home and should have a care giving relative supported by a professional caregiver giver to manage daily activities and incontinence related tasks.

3. Subject is willing and able to provide informed consent and to participate in the clinical investigation or has a legally designated representative willing to provide informed consent on behalf of the subject.

4. Care giving relative is willing and able to provide informed consent to participate in the clinical investigation.

5. If incontinence is managed by pharmaceuticals, the dose regime is stable.

6. Subject and care giving relative (if any) are over 18 years of age.

7. Post-menopausal women or no longer of child-bearing potential

Exclusion Criteria:

1. Subject is cared for in a professional establishment or is institutionalized.

2. Subject has severe incontinence product related skin problems corresponding to scores equal to or higher than 4 in the skin health assessment, as judged by the investigator.

3. Subject suffers from regular faecal incontinence more than once a week.

4. Subject has any type of urinary catheter(s) resulting in improved/treated urinary incontinence.

5. Any other condition that may make participation in the clinical investigation inappropriate, as judged by investigator.

6. Subject or care giving relative is incapable or unwilling to collect used products and fill out the bag label required for the clinical investigation.

7. Participation in another investigational study of a drug, biologic, or medical device within 30 days prior to entering the clinical investigation or planned during the clinical investigation as well as prior participation in this investigation

8. Subject is pregnant or nursing or of childbearing potential.

9. Investigator suspects that subject or care giving relative has an alcohol or drug addiction.

10. Subject and/or caregiving relative is closely affiliated with or in hierarchical dependency of the Sponsor, PI, or CRO involved in this study

11. Subject's incontinence is currently managed by more than 1 type of AHP's

12. Surgery or hospitalization less than 4 weeks prior to study inclusion or planned surgery hospitalization during study conduct.

Related Conditions & MeSH terms

• Urinary Incontinence

Intervention

Device:
• SN2
Investigational device absorption level Normal
• SP3
Investigational device absorption level Plus

Locations

Country	Name	City	State
Germany	Diakonissen-Stiftungs-Krankenhaus Speyer	Speyer

Sponsors (2)

Lead Sponsor	Collaborator
Essity Hygiene and Health AB	Smerud Medical Research Germany Ltd

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reported number of urinary leakages	The proportion of products experiencing urine leakage over the 10 day test period is compared between the investigational and reference product. Labels are used to collect this information for each used product	20 days
Secondary	Incidence of safety events	The number and severity of reported safety events are collected and compared for the intervention and reference products	20 days
Secondary	Product Satisfaction questionnaire	To evaluate caregiver perception of and experience in using the products. Overall satisfaction score with investigational product as compared to the reference product using a 5-point likert scale.	20 days
Secondary	Skin health questionnaire	To evaluate subject's skin health for the investigational product as compared to the reference product as part of the questionnaire	20 days